According to World Alzheimer Report 2015 from Alzheimer’s Disease International, 46.8 million people worldwide are living with dementia in 2015. This number will almost double every 20 years, reaching 74.7 million in 2030 and 131.5 million in 2050. It is well known there is still no drug capable of improving Alzheimer’s disease.
Alzheimer’s disease is one of the most common form of dementia which accounts for 60 to 80% of all dementia cases. Statistics from Alzheimer’s Disease International record approximate 44 million people worldwide living with Alzheimer’s disease or related dementia in 2016. It is the 6th leading cause of death in the United States, with one in three elderly dying of Alzheimer’s or other forms of dementia. Alzheimer’s may be among the costliest diseases for societies in Europe and the United States.
Ginsberg has first reported the close correlation between plasmalogen and Alzheimer’s disease, that is, plasmalogen was decreased in post mortem brain samples of Alzheimer’s disease, compared with in other neurodegenerative diseases.